Jyong Biotech

Jyong Biotech EBITDA per Employee

The EBITDA per Employee of Jyong Biotech (MENS) as of Nov 20, 2026 is -89,896.55 USD. In the previous year, EBITDA per Employee was -67,344.83 USD — a change of 33.49% (lower).

EBITDA per Employee

-89,896.55USD

YoY

33.49%

Last updated:

EBITDA per Employee of Jyong Biotech is 2025 -89,896.55 USD. EBITDA per Employee of Jyong Biotech was 2024 -67,344.83 USD. It decreases by 33.49% lower compared to the previous year.

The Jyong Biotech EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2020
-84,344.83 USD
Jan 1, 2021
-82,896.55 USD
Jan 1, 2022
-93,655.17 USD
Jan 1, 2023
-92,655.17 USD
Jan 1, 2024
-67,344.83 USD
Jan 1, 2025
-89,896.55 USD
The Jyong Biotech EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-89,896.55USD+33.49%
-67,344.83USD-27.32%
-92,655.17USD-1.07%
-93,655.17USD+12.98%
-82,896.55USD-1.72%
-84,344.83USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jyong Biotech Stock analysis

What does Jyong Biotech do? Jyong Biotech Ltd. develops and commercializes plant-derived biotechnology products, focusing on urinary system diseases. The company's primary product is MCS-2, a botanical drug candidate for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), and PCP, a clinical-stage botanical drug candidate for prostate cancer prevention. These products target markets in the United States, European Union, and Asia. The firm generates revenue through the development and eventual commercialization of these innovative botanical drug candidates, with MCS-2 and PCP representing key stages in its pipeline. Jyong Biotech's business model centers on advancing its botanical drug candidates through clinical and preclinical stages. The company employs 29 full-time employees to manage research, development, and commercialization efforts. Its focus on plant-derived treatments for urinary system diseases positions it to serve patients and healthcare providers in the U.S., EU, and Asian markets. The firm's revenue streams will primarily come from the successful development and sale of MCS-2 and PCP once they reach commercialization. The company's product portfolio includes MCS-2, PCP, and other preclinical-stage botanical drug candidates. These products are developed for specific medical conditions, with MCS-2 targeting BPH/LUTS and PCP targeting prostate cancer prevention. The firm's strategy involves leveraging its botanical drug development expertise to enter key global markets. Revenue will be generated once these products are approved and sold in the U.S., EU, and Asia. Jyong Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jyong Biotech stock

EBITDA per Employee of Jyong Biotech is -89,896.55 USD in 2025.

EBITDA per Employee of Jyong Biotech changed from -67,344.83 USD to -89,896.55 USD, representing a 33.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Jyong Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Jyong Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Jyong Biotech

All Key Metrics — Jyong Biotech